All In Biotech

Drug Trial Radar · NCT03008083

Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease

Last checked: Nov 19, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,446 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,446

Planned (sponsor's estimate)

Start

Jan 10, 2019

Primary completion

Dec 2020

Study completion Oct 2022

Sponsor

Sponsor type
Industry
First posted
Jan 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk™ stent). All participants met the inclusion criteria begin taking aspirin and open-label thienopyridine therapy before index procedure, and will be 1:1 randomized to 3 months or 12 month of DAPT at index procedure.

Conditions

  • Drug-Eluting Stents
  • Percutaneous Coronary Intervention

Interventions

  • 3 months DAPTDrug

    Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.

  • 12 months DAPTDrug

    Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Net Adverse Clinical and Cerebral Events (NACCE)Time frame: At 18 months after index procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Zhongshan Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.